Proguanil is a prophylactic antimalarial drug, which works by stopping the malaria parasite, Plasmodium falciparum and Plasmodium vivax, from reproducing once it is in the red blood cells. It does this by inhibiting the enzyme, dihydrofolate reductase, which is involved in the reproduction of the parasite.
For the causal prevention and suppression of malaria caused by susceptible strains of P. falciparum and other species of Plasmodium found in some geographical areas of the world.
Richmond Pharmacology Limited, London, United Kingdom
Uniformed Services University, Bethesda, Maryland, United States
Universitätsklinikum Tübingen, Institut für Tropenmedizin, Tübingen, Germany
Clinical Pharmacology, University of Southern Denmark, Odense, Fyn, Denmark
Leiden University Medical Centre, Leiden, Netherlands
Department of Paediatrics and Child Health, University of Ilorin Teaching Hospital, Ilorin, Kwara, Nigeria
New Nyanza Provincial Hospital, Kisumu, New Nyanza, Kenya
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.